Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251

Margherita Rosati1, Agneta von Gegerfelt, Patricia Roth

  • 1Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, Bldg. 535, Rm. 210, National Cancer Institute at Frederick, Frederick, Maryland 21702, USA.

Journal of Virology
|June 16, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Feasibility and optimization of a novel, cranially-mounted deep brain stimulation device for children with epilepsy - the CADET Pilot study.

Brain stimulation·2026
Same author

Application of Electric-Field-Optimized Augmented Reality-Guided Neuronavigation in Transcranial Magnetic Stimulation.

Journal of clinical medicine·2026
Same author

Repetitive transcranial magnetic stimulation as adjunctive therapy in adult patients with drug-resistant epilepsy-A systematic review and meta-analysis.

Epileptic disorders : international epilepsy journal with videotape·2026
Same author

Electrical Cortical Stimulation for Language Mapping in Epilepsy Surgery-A Systematic Review.

Brain sciences·2025
Same author

Seizure forecasting by tracking cortical response to electrical stimulation.

Epilepsia·2025
Same author

Highly immunogenic DNA/LION nanocarrier vaccine potently activates lymph nodes inducing long-lasting immunity in macaques.

iScience·2025
This summary is machine-generated.

DNA vaccines enhanced with fusion proteins significantly reduced viral load in macaques after SIV challenge. Combining native and modified antigens created balanced immune responses, controlling viremia for eight months.

Area of Science:

  • Immunology
  • Vaccinology
  • Virology

Background:

  • DNA immunization is a promising vaccination strategy.
  • Enhancing immunogenicity of viral antigens is crucial for vaccine efficacy.
  • Simian immunodeficiency virus (SIV) infection in macaques serves as a model for HIV research.

Purpose of the Study:

  • To evaluate DNA immunization efficacy in rhesus macaques against pathogenic SIVmac251.
  • To improve the immunogenicity of viral antigens (Gag and Env) using fusion proteins.
  • To assess the impact of combining native and modified antigen forms on immune responses and viral load control.

Main Methods:

  • Generation of DNA expression vectors encoding native Gag and Env proteins, and fusion proteins with MCP3 or beta-catenin (CATE).

Related Experiment Videos

  • Immunization of rhesus macaques with DNA vaccines.
  • Mucosal challenge with pathogenic SIVmac251.
  • Measurement of antibody responses, viral load, and T-cell responses (enzyme-linked immunospot assay).

    • Main Results:

    • Immunization with MCP3-tagged fusion proteins elicited stronger antibody responses.
    • Vaccinated macaques showed a statistically significant decrease in viral load post-challenge (P = 0.010).
    • A combination of native and modified antigens (MCP3 and CATE fusions) resulted in the greatest viral load reduction (P = 0.0059).
    • Gag and Env-specific T-helper responses correlated with viremia control.

    Conclusions:

    • DNA vaccines expressing fusion proteins enhance immunogenicity and antibody responses.
    • Combining native and modified antigen forms in DNA vaccines leads to more balanced immune responses.
    • This combined DNA vaccine approach significantly reduces and controls viremia for an extended period following pathogenic SIV challenge.